CTOs on the Move


 
Built on the legacy of James Edward Hanger, the first amputee of the American Civil War, Hanger, Inc. (NYSE: HGR) delivers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions to the broader market. Hanger`s Patient Care segment is the largest owner and operator of O&P patient care clinics with in excess of 730 locations nationwide. Through its Products and Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides therapeutic solutions. Steeped in over 150 years of clinical excellence and innovation, Hanger`s vision is to be the partner of choice ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.hanger.com
  • 10910 Domain Drive Suite 300
    Austin, TX USA 78758
  • Phone: 512.777.3800

Executives

Name Title Contact Details
Lety Nettles
EVP Chief Information Officer Profile
Caleb Magee
Chief Information Security Officer Profile
Alan Mitchell
Chief Information Security Officer Profile
Alan Mitchell
Vice President of Security and Infrastructure and Chief Information Security Officer Profile
Scott Ranson
Chief Information Officer Profile

Funding

Hanger raised $605M on 03/05/2018

Similar Companies

Alaska Native Tribal Health Consortium

The Alaska Native Tribal Health Consortium is a not-for-profit tribal health organization managed by Alaska Native tribal governments and their regional health organizations.

Saint Margaret Mercy Healthcare Centers

Saint Margaret Mercy Healthcare Centers is a Hammond, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CancerConsultants.com

CancerConsultants.com is a Ketchum, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Widex

Explore the possibilities of Widex hearing solutions and hearing aids for your lifestyle. Find your next hearing aids and get a risk-free trial!

Menlo Therapeutics

We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.